Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review

Arnd Jacobi, Anke Mayer, Matthias Augustin, Arnd Jacobi, Anke Mayer, Matthias Augustin

Abstract

Introduction: Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms. The aim of this publication is to systematically review the role of currently used emollients and keratolytics in the treatment of psoriasis.

Methods: A systematic literature search was conducted in Medline via PubMed regarding reviews, meta-analyses, and trials published from January 1983 to December 2013 dealing with topical administration of emollients and keratolytics in patients with psoriasis. A subsequent search in EMBASE regarding clinical trials published from 1983 to 2013 was performed to complement the findings.

Results: A total of 60 publications met the inclusion criteria for full-text evaluation. While current reviews, meta-analyses, and guidelines state that adjuvant therapy with emollients and keratolytics should be an obligatory part in the therapy of psoriasis to facilitate descaling and/or penetration enhancement, comprehensive trials on these agents are missing, with the exception of combination products containing salicylic acid and corticosteroids. In the mentioned trials, addition of salicylic acid was beneficial in inducing a more rapid onset of action as well as a reduction of severity parameters and the area affected. However, its use has substantial limitations in young children, in patients with renal/hepatic impairment, with widespread psoriasis, those undergoing phototherapy, or those concomitantly treated with calcipotriene/systemic salicylates.

Conclusion: In view of these shortcomings, there is a need for well-designed studies on suitable keratolytic alternatives to salicylic acid offering an indisputable positive benefit-risk ratio.

References

    1. Cohen SN, Baron SE, Archer CB. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012;37(Suppl 1):13–18. doi: 10.1111/j.1365-2230.2012.04337.x.
    1. Cordoro KM. Topical therapy for the management of childhood psoriasis: part I. Skin Therapy Lett. 2008;13:1–3.
    1. Akamine KL, Gustafson CJ, Yentzer BA, et al. A double-blind, randomized clinical trial of 20% alpha/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis. J Drugs Dermatol. 2013;12:855–859.
    1. Federman DG, Froelich CW, Kirsner RS. Topical psoriasis therapy. Am Fam Physician. 1999;59(957–62):964.
    1. Sticherling M, Augustin M, Boehncke W, et al. Therapy of psoriasis in childhood and adolescence—a German expert consensus. J Dtsch Dermatol Ges. 2011;9:815–823.
    1. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001;76:943–949. doi: 10.1016/S0025-6196(11)62116-2.
    1. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–485. doi: 10.1016/j.jaad.2009.03.027.
    1. Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013;168:954–967. doi: 10.1111/bjd.12276.
    1. Naldi L, Rzany B. Psoriasis (chronic plaque). Clin Evid (Online). 2009; pii: 1706.
    1. Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version) Arch Dermatol Res. 2012;304:87–113. doi: 10.1007/s00403-012-1214-8.
    1. Pauporte M, Maibach H, Lowe N, et al. Fluocinoloneacetonide topical oil for scalp psoriasis. J Dermatolog Treat. 2004;15:360–364. doi: 10.1080/09546630410023566.
    1. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J ClinDermatol. 2003;4:771–788.
    1. Chiricozzi A, Chimenti S. Effective topical agents and emerging perspectives in the treatment of psoriasis. Expert Rev Dermatol. 2012;7:283–293. doi: 10.1586/edm.12.18.
    1. Nast A, Boehncke W, Mrowietz U, et al. S3—guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10(Suppl 2):S1–S95. doi: 10.1111/j.1610-0387.2012.07919.x.
    1. Birgin B, Fetil E, Ilknur T, TahsinGüneş A, Ozkan S. Effects of topical petrolatum and salicylic acid upon skin photoreaction to UVA. Eur J Dermatol. 2005;15:156–158.
    1. Kornhauser A, Coelho SG, Hearing VJ. Applications of hydroxy acids: classification, mechanisms and photoactivity. Clin Cosmet Investig Dermatol. 2010;3:135–142. doi: 10.2147/CCID.S9042.
    1. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222:363–374. doi: 10.1159/000329026.
    1. Kinney MA, Feldman SR. What’s new in the management of psoriasis? G Ital Dermatol Venereol. 2009;144:103–117.
    1. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005;141:43–46. doi: 10.1001/archderm.141.1.43.
    1. Ryan S. Psoriasis: characteristics, psychosocial effects and treatment options. Br J Nurs. 2008;17:284–290. doi: 10.12968/bjon.2008.17.5.28823.
    1. Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers and keratolytic agents in psoriasis. Clin Dermatol. 2008;26:380–386. doi: 10.1016/j.clindermatol.2008.01.015.
    1. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38:16–24. doi: 10.1046/j.1365-4362.1999.00500.x.
    1. Finlay A. Emollients as adjuvant therapy for psoriasis. J Dermatol Treat. 1997:25–27.
    1. Hendriks AGM, Keijsers RRMC, de Jong EMGJ, Seyger MMB, van de Kerkhof PCM. Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2013;27:399–410. doi: 10.1111/j.1468-3083.2012.04640.x.
    1. Childhood psoriasis: often favorable outcome. Prescrire Int. 2009;18:275.
    1. Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs. 2006;18:227–233.
    1. Raut AS, Prabhu RH, Patravale VB. Psoriasis clinical implications and treatment: a review. Crit Rev Ther Drug Carrier Syst. 2013;30:183–216. doi: 10.1615/CritRevTherDrugCarrierSyst.2013005268.
    1. Tidman MJ. Improving outcomes in patients with psoriasis. Practitioner. 2013;257(27–30):3.
    1. Berne B, Blom I, Spångberg S. Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base. A single-blind controlled study. Acta Derm Venereol. 1990;70:474–477.
    1. Boyvat A, Erdi H, Birol A, Gurgey E. Interaction of commonly used emollients with photochemotherapy. Photodermatol Photoimmunol Photomed. 2000;16:156–60.
    1. Kristensen B, Kristensen O. Topical salicylic acid interferes with UVB therapy for psoriasis. Acta Derm Venereol. 1991;71:37–40.
    1. Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol. 1995;32:469–471. doi: 10.1016/0190-9622(95)90071-3.
    1. van Duijnhoven, Mirella WFM, Hagenberg R, et al. Novel quantitative immunofluorescent technique reveals improvements in epidermal cell populations after mild treatment of psoriasis. Acta Derm Venereol. 2005;85:311–317.
    1. Rim JH, Jo SJ, Park JY, Park BD, Youn JI. Electrical measurement of moisturizing effect on skin hydration and barrier function in psoriasis patients. Clin Exp Dermatol. 2005;30:409–413. doi: 10.1111/j.1365-2230.2005.01773.x.
    1. Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis. 2000;66:4–11.
    1. Watsky KL, Freije L, Leneveu MC, Wenck HA, Leffell DJ. Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis. 1992;50:383–386.
    1. Singh S, Gopal J, Mishra RN, Pandey SS. Topical 0.05% betamethasone dipropionate: efficacy in psoriasis with once a day vs. twice a day application. Br J Dermatol. 1995;133:497–498. doi: 10.1111/j.1365-2133.1995.tb02693.x.
    1. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol. 1996;76:353–356.
    1. Pan M, Heinecke G, Bernardo S, Tsui C, Levitt J. Urea: a comprehensive review of the clinical literature. Dermatol Online J. 2013;19:20392.
    1. Gip L, Lundberg M. A double-blind controlled trial of a new antipsoriatic cream containing urea and sodium chloride. CurrTher Res. 1985;37:797–804.
    1. Fredriksson T, Lundberg M. A blind controlled comparison between a new cream (“12 + 12”), its vehicle and salicylic acid in petrolatum on psoriatic plaques. Curr Ther Res. 1985;37:805–809.
    1. Lakshmi PK, Bhaskaran S. Phase II study of topical niosomal urea gel-an adjuvant in the treatment of psoriasis. Int J Pharm Sci Rev Res. 2011;7(1):1–7.
    1. Vena GA, Cassano N, Agnusdei CP, et al. Treatment of psoriasis vulgaris with calcipotriol betamethasone dipropionate combination followed by calcipotriol and assessment of the adjuvant basic use of urea-based emollients. Eur J Inflamm. 2005;3:37–41.
    1. Shemer A, Nathansohn N, Kaplan B, Weiss G, Newman N, Trau H. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol. 2000;39:532–534. doi: 10.1046/j.1365-4362.2000.00986-3.x.
    1. Taube KM, Fiedler H, Wohlrab W, Wozniak KD. Untersuchungen zur Kurzzeitbehandlung der Psoriasis vulgaris mit Dithranol unter Harnstoffzusatz. Dermatol Monatsschr. 1985;171:650–653.
    1. Koo J, Cuffie CA, Tanner DJ, et al. Mometasonefuroate 0.1%-salicylic acid 5% ointment one-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res. 1983;11:108–112. doi: 10.1177/030006058301100208.
    1. Berardesca E, PieroVignoli G, Distante E, Rona C. Effects of glycolic acid on psoriasis. Clin Exp Dermatol. 1998;23:190–191. doi: 10.1046/j.1365-2230.1998.00361.x.
    1. Kostarelos K, Teknetzis A, Lefaki I, Ioannides D, Minas A. Double-blind clinical study reveals synergistic action between alpha-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis. J Eur Acad Dermatol Venereol. 2000;14:5–9. doi: 10.1046/j.1468-3083.2000.00006.x.
    1. Chan CS, Van Voorhees, Abby S, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60:962–71.
    1. Cox NH, Sharpe G. Emollients, salicylic acid and ultraviolet erythema. Lancet. 1990;335:53–54. doi: 10.1016/0140-6736(90)90183-6.
    1. Fetil E, Ozka S, Soyal MC, Ilknur T, Erdem Y, Güneş AT. Effects of topical petrolatum and salicylic acid on the erythemogenicity of UVB. Eur J Dermatol. 2002;12:154–156.
    1. Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm. 2000;57:645–659.
    1. Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trüeb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23:1435–1444. doi: 10.1111/j.1468-3083.2009.03372.x.
    1. Kircik L. Salicylic Acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis. J Drugs Dermatol. 2011;10:270–273.
    1. Going SM, Guyer BM, Jarvie DR, Hunter JA. Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol. 1986;11:260–262. doi: 10.1111/j.1365-2230.1986.tb00457.x.
    1. Nolting S, Hagemeier HH. Therapie erythrosquamöser Dermatosen. Betamethason-Dipropionat plus Salizylsäure im Vergleich zu Betamethason-Dipropionat-Lösung. Fortschr Med. 1983;101:1679–1683.
    1. Elie R, Durocher LP, Kavalec EC. Effect of salicylic acid on the activity of betamethas. Curr Ther Res. 1983;34:459–468.
    1. Tiplica G, Salavastru CM. Mometasonefuroate 0.1% and salicylic acid 5% vs. mometasonefuroate 0.1% as sequential local therapy in psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:905–12.
    1. Katz H, Tanner D, Cuffie CA, et al. A comparison of the efficacy and safety of the combination mometasonefuroate 0.1%/salicylic acid 5% ointment with each of its components in psoriasis. J Dermatolog Treat. 1998;9:151–156. doi: 10.3109/09546639809160546.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa